REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic ...
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ...
Please provide your email address to receive an email when new articles are posted on . A large cohort study showed high prevalence of bilateral diabetic macular edema at first visit. The intensity of ...
– The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME treated with Vabysmo who identify as African American, Black, Hispanic and ...
Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. What we’ve learned consistently is that ...
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME) Results Consistent with Data Released Last Month Showing Patients with DME Who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback